"" Ralph Moss—Cancer Consultant: THE STRANGE CASE OF GcMAF

Tuesday, July 5, 2016

THE STRANGE CASE OF GcMAF

GcMAF is another "alternative" cancer treatment that has gotten a great deal of attention in the past few years. 

There is a very complete discussion of GcMAF at the Web site of the Anticancer Fund (formerly called Reliable Cancer Therapies) and so I do not need to reinvent the wheel. Interested readers can go to their Web site and read the details of their very thorough investigation. (http://www.anticancerfund.org/therapies/gcmaf

When Nobuto Yamamoto, PhD, first announced the discovery of his “cure” for stage IV cancer in 2008 I was excited. Yamamoto was a biology researcher in Philadelphia for many years. But since his retirement about 20 years ago he has been the director of something called the Socrates Institute for Therapeutic Immunology. There is no Web site nor Internet listing for this institute. The address that appears in his papers, 1040 66th Avenue, Philadelphia, seems to be a private house in a residential neighborhood. I finally got Dr. Yamamoto on the phone, but he was unable to arrange a time for me to meet him. Frankly, he sounded very frail and forgetful (He is now over 90 years old.)

The Anticancer Fund authors also tried to track down the various contributors to Yamamoto’s papers:
“After months of trying to get additional information on the patients and scientists involved in this research we came to the conclusion that these data should not be relied on since there are important issues in the methodology and procedures. The same group has also presented their results to different scientific conferences and we could confirm that one co-author’s participation was denied by the person himself, while we could not contact others besides Nobuto Yamamoto.” (Ibid.)
It should be noted that most of the articles claiming that GcMAF is an effective treatment of breast and colorectal cancer have been retracted by the journals in question. In the opinion of the Anticancer Fund authors, 

“GcMAF has not been properly studied in clinical trials and its laboratory results still need to be confirmed independently. So far, all claims on the efficacy of this product have no solid scientific basis.”
I have visited with the Anticancer Fund in Belgium and know some of the main people there. They are not motivated by a bias against complementary treatments. Quite the opposite. They simply want such treatments to be realistically presented and based on genuine science. In the case of GcMAF, to put it mildly, they came up empty handed.